Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals was founded in 2013 by Joshua Cohen and Justin Klee, who began investigating neurodegeneration as undergraduates at the University of Pennsylvania. Their thesis — that simultaneously targeting mitochondrial dysfunction and endoplasmic reticulum stress could slow diseases like amyotrophic lateral sclerosis — led to the combination therapy later known as RELYVRIO in the U.S. and ALBRIOZA in Canada. The company incorporated in Cambridge, Massachusetts, and raised early capital from Morningside Ventures and other life-science backers before listing on Nasdaq in January 2022, raising $190 million in its IPO. The firm operates with a singular therapeutic focus on neurodegenerative diseases. Its primary asset, sodium phenylbutyrate and taurursodiol, was tested across ALS, Alzheimer’s disease, and Wolfram syndrome. Amylyx’s most notable engagement was with the FDA, which initially declined approval based on a single Phase II trial, then reversed course in September 2022 following a rare second advisory committee hearing where patient-community testimony proved decisive. This made RELYVRIO the third ALS drug to reach U.S. patients in three decades and the first to gain approval following a regulatory reversal of that nature. The company advanced additional pipeline candidates, including AMX0035 in progressive supranuclear palsy, and established a named-patient and compassionate-use infrastructure in Europe before formal EMA authorization. Amylyx scaled rapidly post-approval, expanding its commercial team and launching RELYVRIO with a list price of about $158,000 per year. By early 2023, the company reported quarterly product revenue exceeding $100 million, reaching a market capitalization above $2 billion. As a publicly listed entity, its governing board includes seasoned pharmaceutical operators, though Cohen and Klee retained Co-CEO control. The company disclosed a commitment to access programs in low- and middle-income countries. A defining operational event came in March 2024: Amylyx announced it would voluntarily withdraw RELYVRIO from the U.S. and Canadian markets after the Phase III PHOENIX trial failed to show a statistically significant benefit. The company initiated a 70% staff reduction and pivoted resources toward its remaining early-stage programs, including GLP-1 receptor antagonist work. What distinguishes Amylyx within the biotech landscape is its regulatory legacy. The firm’s approval-and-withdrawal cycle became a Rorschach test for the FDA’s accelerated approval pathway in neurodegenerative disease. Few companies of its size have so directly shaped the debate on evidentiary standards for fatal, high-urgency conditions. The firm now operates in a materially reduced form, making it a case study in post-study succession planning and the survival mechanics of a single-asset public biotech after a pivotal trial failure.